Key facts
- Heecap’s last known valuation is $3.8M (Dec 2024).
- It has raised $670K; the latest was Early Stage VC ($520K) in Dec 2024.
- Notable investors include European Innovation Council, CDTI Innvierte, Institut Català de Finances, CRAASH Barcelona, Cecot Healthcare Pre-Accelerator — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Heecap
- ·The full record, as it builds
Funding rounds
No funding rounds for Heecap are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Heecap
Developer of respiratory muscle functioning technology designed to enhance extubation success for patients on mechanical ventilation in intensive care units. The company specializes in transcutaneous electrostimulation of respiratory muscles, helping hospitals reduce ICU stays and improving patients' quality of life.
- Sector
- Healthcare
- HQ
- Barcelona, Spain
- Founded
- 2021
- Employees
- 9
- Website
- heecap.com/
- Ownership
- Privately Held (backing)
Heecap doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Heecap shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Heecap in its N-PORT filings yet. We sweep new filings monthly.